Last edition
News about "Professor Binghe Xu"
HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.
Professor Binghe Xu | 16/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members